Countdown to Ethereum Pectra Upgrade Activation: Learn more
$2.59T
Total marketcap
$234.17B
Total volume
BTC 60.57%     ETH 7.22%
Dominance

NLS Pharmaceutics NLSPW Stock

0.006 USD {{ price }} -39.999996% {{change_pct}}%
Exchange
NasdaqCM
Market Cap
0 USD
LOW - HIGH [24H]
0.0009 - 0.0087 USD
VOLUME [24H]
324.46K USD
{{ volume }}
P/E Ratio
0
Earnings per share
0 USD

NLS Pharmaceutics Price Chart

NLS Pharmaceutics NLSPW Financial and Trading Overview

NLS Pharmaceutics stock price 0.0060 USD
Previous Close 0.02 USD
Open 0.05 USD
Bid 0 USD x 0
Ask 0 USD x 0
Day's Range 0.03 - 0.06 USD
52 Week Range 0.01 - 0.17 USD
Volume 40.76K USD
Avg. Volume 10.58K USD
Market Cap N/A
Beta (5Y Monthly) -0.532
PE Ratio (TTM) N/A
EPS (TTM) 0 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A

NLSPW Valuation Measures

Enterprise Value N/A
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) N/A
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA N/A

Trading Information

NLS Pharmaceutics Stock Price History

Beta (5Y Monthly) -0.532
52-Week Change N/A
S&P500 52-Week Change N/A
52 Week High 0.17 USD
52 Week Low 0.01 USD
50-Day Moving Average 0.03 USD
200-Day Moving Average 0.07 USD

NLSPW Share Statistics

Avg. Volume (3 month) 10.58K USD
Avg. Daily Volume (10-Days) 17.27K USD
Shares Outstanding N/A
Float 19.7M
Short Ratio N/A
% Held by Insiders N/A
% Held by Institutions N/A
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends N/A
Most Recent Quarter (mrq) N/A
Next Fiscal Year End N/A

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -132.68%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -11795655 USD
Net Income Avi to Common (ttm) -12172029 USD
Diluted EPS (ttm) N/A
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 897.68K USD
Total Cash Per Share (mrq) 0.02 USD
Total Debt (mrq) 1.63M USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 0.23
Book Value Per Share (mrq) -0.272

Cash Flow Statement

Operating Cash Flow (ttm) -9684466 USD
Levered Free Cash Flow (ttm) -4995114 USD

Profile of NLS Pharmaceutics

Country United States
State N/A
City Zurich
Address The Circle 6
ZIP 8058
Phone 41 44 512 21 50
Website https://nlspharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees N/A

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy associated with narcolepsy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with NeuroLife-Sciences SAS for use of mazindol for the treatment of ADHD; and Eurofarma Laboratorios S.A. for commercialization and distribution of Nolazol in Latin America. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Q&A For NLS Pharmaceutics Stock

What is a current NLSPW stock price?

NLS Pharmaceutics NLSPW stock price today per share is 0.0060 USD.

How to purchase NLS Pharmaceutics stock?

You can buy NLSPW shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for NLS Pharmaceutics?

The stock symbol or ticker of NLS Pharmaceutics is NLSPW.

Which industry does the NLS Pharmaceutics company belong to?

The NLS Pharmaceutics industry is Biotechnology.

How many shares does NLS Pharmaceutics have in circulation?

The max supply of NLS Pharmaceutics shares is 0.

What is NLS Pharmaceutics Price to Earnings Ratio (PE Ratio)?

NLS Pharmaceutics PE Ratio is now.

What was NLS Pharmaceutics earnings per share over the trailing 12 months (TTM)?

NLS Pharmaceutics EPS is 0 USD over the trailing 12 months.

Which sector does the NLS Pharmaceutics company belong to?

The NLS Pharmaceutics sector is Healthcare.

Stocks Related By Sector

Stocks Related By Industry

Stocks Related By Marketcap